An association between liraglutide treatment and reduction in excessive daytime sleepiness in obese subjects with type 2 diabetes

@inproceedings{GomezPeralta2015AnAB,
  title={An association between liraglutide treatment and reduction in excessive daytime sleepiness in obese subjects with type 2 diabetes},
  author={Fernando Gomez-Peralta and Cristina Coelho de Abreu and Jos{\'e} Carlos Castro and Elvira Alcarria and Margarita Cruz-Bravo and Maria Jes{\'u}s Garcia-Llorente and Cristina Albornos and Concepci{\'o}n Fern{\'a}ndez Moreno and Mar{\'i}a Elena Cepeda and Francisca Alm{\'o}dovar},
  booktitle={BMC endocrine disorders},
  year={2015}
}
BACKGROUND The main purpose of the present study is to evaluate whether treatment with long-acting human glucagon-like peptide-1 liraglutide was associated with an improvement of excessive daytime sleepiness (EDS) in obese subjects with type-2 diabetes. METHODS This single-centre retrospective study included 158 obese (body mass index [BMI] ≥ 30 kg/m(2)) adult subjects with type-2 diabetes who were initiated with liraglutide treatment at least 3 months before study inclusion. Data of the… CONTINUE READING
BETA
1
Twitter Mention

Citations

Publications citing this paper.
SHOWING 1-3 OF 3 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 31 REFERENCES

An overview of the pharmacokinetics, efficacy and safety of liraglutide

B. Bode
  • Diabetes Res Clin Pract
  • 2012
VIEW 1 EXCERPT

Effects of glucagonlike peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials

T Vilsboll, M Christensen, AE Junker, FK Knop, LL. Gluud
  • BMJ. 2012;344:d7771
  • 2012
VIEW 1 EXCERPT

Similar Papers

Loading similar papers…